Furthermore, MLN0128 has been demonstrated to have therapeutic efficacy in several xenograft animal models of human cancers alone or in combination with receptor tyrosine kinase (RTK) inhibitors or PI3K/Akt inhibitor [25–30]. This evidence concerns the gene AKT1 and cancer.